Specialty Care profit fell $18.50 M as Perrigo's segments lost ground
Perrigo's three businesses earned $130.50 M of operating income this quarter, down from $148.00 M a year earlier, and Specialty Care took the biggest hit. Its operating income fell $18.50 M to $47.80 M. Management blames "unfavorable gross profit flow through" from prior-year manufacturing volume headwinds and unfavorable mix, plus $4.0 million more spent on advertising to support second half growth initiatives. Self Care, which brings in 56% of sales, also slipped, to $78.70 M from $93.90 M. Only Infant Formula improved, swinging to a $4.00 M profit.
Why is Self Care slipping? Management cites "unfavorable net pricing impacts and lower consumption across both the U.S. and Europe", partly from a weaker cough and cold season that left retailers holding less inventory. Its sales fell 3.7% from a year earlier, gentler than the 12% drop of the quarter before. Infant Formula sales jumped 23%, but management credits mainly the "timing of contract infant formula shipments". Timing gains can reverse in a later quarter. And All Other lost $24.10 M of sales, largely because it held the Dermacosmetics business sold in April 2026.
For investors, mix matters: Specialty Care keeps about 21% of its sales as operating income and Infant Formula about 4.0%, so formula's growth does little for profit. The businesses' combined margin fell to 14.4% from 16.2%. In Self Care, management points to "benefits from the Operational Enhancement Program" cutting operating expenses by $12.0 million, yet head-office costs and other items still took about 82% of segment profit. Watch Self Care pricing and whether extra advertising lifts Specialty Care. If that advertising push fails, where does Perrigo's profit growth come from?

